Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib and Trametinib After Radiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma
NCT03919071Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Feb 2020
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of dabrafenib + trametinib and trametinib in glioma, sponsored by National Cancer Institute. Primary endpoint: Event-Free Survival up to 5 years. Started Feb 2020; status: active, not recruiting.
02
Drugs
dabrafenib + trametinibtrametinib
03
Conditions
glioma
Beyond the preview
Go deeper on NCT03919071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03919071.